Additionally, our findings demonstrated noteworthy differences in PABPN1 expression across clinical subgroups of urogenital cancers, aligning with prior research highlighting varying PABPN1 expression in different stages of prostate cancer (11). Here, PABPN1 is linked to prostate carcinoma.